Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribonuclease H2 subunit C (RNASEH2C) is one of the three components that form the human RNase H2 heterotrimeric complex, an essential nuclear enzyme involved in the degradation of RNA/DNA hybrids and the removal of single ribonucleotides incorporated into genomic DNA during replication. This enzymatic activity helps maintain genome stability by preventing the accumulation of ribonucleotides in DNA, which can cause genomic instability if left unrepaired. The complex is also implicated in DNA replication, error repair, and the suppression of inappropriate immune activation by removing nucleic acid structures that could otherwise trigger innate immune responses. Mutations in RNASEH2C result in a loss of RNase H2 function and cause Aicardi-Goutières syndrome, a rare genetic disorder characterized by neurological dysfunction and autoimmunity due to the intracellular accumulation of DNA/RNA fragments that stimulate immune activation[1][2][3][4][5].
Hydrolytic cleavage of RNA in RNA/DNA hybrids[4], Removal of single ribonucleotides in DNA
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribonuclease H2 subunit C (RNASEH2C).